Cargando…
Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer
INTRODUCTION: The treatment response to neoadjuvant immunochemotherapy varies among patients with potentially resectable non-small cell lung cancers (NSCLC) and may have severe immune-related adverse effects. We are currently unable to accurately predict therapeutic response. We aimed to develop a r...
Autores principales: | Liu, Chaoyuan, Zhao, Wei, Xie, Junpeng, Lin, Huashan, Hu, Xingsheng, Li, Chang, Shang, Youlan, Wang, Yapeng, Jiang, Yingjia, Ding, Mengge, Peng, Muyun, Xu, Tian, Hu, Ao’ran, Huang, Yuda, Gao, Yuan, Liu, Xianling, Liu, Jun, Ma, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978193/ https://www.ncbi.nlm.nih.gov/pubmed/36875128 http://dx.doi.org/10.3389/fimmu.2023.1115291 |
Ejemplares similares
-
Incidence and Prognosis Nomogram of Small Solitary Lung Cancer (≤2 cm) With Extra-Thoracic Metastasis at Initial Diagnosis:A Population-Based Study
por: Hu, Ao’ran, et al.
Publicado: (2022) -
Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel–based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer
por: Hu, Xingsheng, et al.
Publicado: (2023) -
Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer
por: Liu, Chaoyuan, et al.
Publicado: (2023) -
Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
por: Li, Kaiyuan, et al.
Publicado: (2023) -
Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)